Briakinumab Biosimilar, Human IL-12/IL-23 mAb
Item Information
Catalog #
Size
Price
Description
Bevacizumab is a humanized IgG1 monoclonal antibody specific for VEGF-A, a cytokine critical for angiogenesis (the growth of new blood vessels) in both normal tissues and tumors. As the first clinically available angiogenesis inhibitor in the United States, Bevacizumab is used for treatment of certain metastatic cancers, lung cancers, renal cancers, ovarian cancers, breast cancers, and glioblastoma multiforme.
Product Overview
Isotype
IgG1 lambda
Source
Produced in a mammalian stable cell line.
Formulation
0.2-uM filtered solution, pH 7.4, no stabilizers or preservatives
Purity
>95% by SDS-PAGE under reducing conditions and HPLC
Endotoxin
<1 EU/mg of the protein by the LAL method.
Specificity/Sensitivity
Binds to human IL-12 and human IL-23.
Storage
4°C if used within 1 month, -20°C otherwise
Shipping Information
Shipped with an ice pack.
Application
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and assays for studying the biological pathways affected by Briakinumab.
For Research Use Only. Not for use in diagnostic procedures.